This month’s newsletter focuses on the latest news and scientific breakthroughs in melanoma research.

This edition features:

• Letter from AIM’s President, Sam Guild
• Notes From the Lab: Novel Targets for Immune Checkpoint Inhibitors
  By Paul Bunk, Ph.D. candidate, Cold Springs Harbor Laboratory
• In Plain English: Neoadjuvant Therapy for Melanoma, and How We Got Here
  By Kim Margolin, M.D., FACP, FASCO
• Clinical Trials Catch Up: An Interview with Joshua M.V. Mammen, M.D., Ph.D., F.A.C.S.
  By Alicia Rowell, Vice President, AIM at Melanoma